Publication date: May 18, 2022 The therapeutic benefit of approved BRAF and MEK inhibitors (BRAFi/MEKi) in patients with brain metastatic BRAF V600E/K-mutated melanoma is limited and transient. Resistance largely occurs ... Read more

Publication date: May 10, 2022 Brain metastasis (BrM) is a major problem associated with cancer-related mortality, and currently, no specific biomarkers are available in clinical settings for early detection. Liquid ... Read more

Publication date: May 09, 2022 Brain metastases from melanoma are no longer uniformly associated with dismal outcomes. Impressive tumor tissue-based (craniotomy) translational research has consistently shown that distinct patient subgroups ... Read more

Publication date: May 01, 2022 PD-L1 is widely expressed in a variety of tumors, including NSCLC, melanoma, renal cell carcinoma, gastric cancer, hepatocellular as well as cutaneous and various leukemias, ... Read more

Publication date: Apr 13, 2022 Molecularly targeted therapeutics have revolutionized the treatment of BRAF -driven malignant melanoma, but the rapid development of resistance to BRAF kinase inhibitors (BRAFi) presents a ... Read more

Publication date: Apr 11, 2022 Whole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain metastasis; however, its efficacy in preventing disease progression and the associated toxicity have ... Read more

Publication date: Apr 01, 2022 Postoperative stereotactic radiosurgery after resection of brain metastases is currently the standard of care. However, rates of leptomeningeal disease (LMD) after postoperative stereotactic radiosurgery have ... Read more